Prophylactic intervention in radiation-leukemia-virus-induced murine lymphoma by the biological response modifier polysaccharide K

Cancer Immunology Immunotherapy

Volumn 41, Issue 6, 1995, Pages 389-396

  Yefenof, E ^a   Gafanovitch, I ^a   Oron, E ^a   Bar, M ^a   Klein, E ^b  

^a HEBREW UNIVERSITY   (Israel)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Lymphoma; Prevention; PSK; RadLV; Superantigen

Indexed keywords

BIOLOGICAL RESPONSE MODIFIER; CONCANAVALIN A; IMMUNOTOXIN; INTERLEUKIN 2; INTERLEUKIN 4; KRESTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION LEUKEMIA VIRUS; THYMUS; VIRUS CARCINOGENESIS;

ADJUVANTS, IMMUNOLOGIC; AGE OF ONSET; ANIMALS; ANTIGEN PRESENTATION; APOPTOSIS; FEMALE; GENE REARRANGEMENT, BETA-CHAIN T-CELL ANTIGEN RECEPTOR; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; LYMPHOMA; MICE; MICE, INBRED C57BL; PRECANCEROUS CONDITIONS; PROTEOGLYCANS; RADIATION LEUKEMIA VIRUS; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; RETROVIRIDAE INFECTIONS; SPECIFIC PATHOGEN-FREE ORGANISMS; SPLEEN; T-LYMPHOCYTE SUBSETS; THYMUS NEOPLASMS; TUMOR VIRUS INFECTIONS;

EID: 0029610239     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/BF01526559     Document Type: Article

References (49)

1. Krestin (PSK)
2. Protective effect of biological response modifiers on murine cytomegalovirus infection
3. The effect of PSK, a protein bound polysaccharide on immune responses against allogeneic antigens
4. Therapeutic effects of PSK and busulfan on the recurrent and metastatic diseases after the surgical removal of 3-methylcholanthrene-induced autochtonous tumors in C57BL/6 mice
5. Activation of the complement by immunostimulants, BCG, OK-432 (Picibani), and PS-K (Krestin) in vitro
6. Diminution of cyclophosphamide-induced suppression of antitumor immunity by an immunomodulator PSK and combined therapeutic effects of PSK and cyclophosphamide on transplanted tumor in rats
7. Restoration of antibody-forming capacities by PS-K in tumorbearing mice
8. Effects of PSK on specific tumor immunity to syngeneic tumor cells
9. Significant prolongation of disease-free period gained by oral polysaccharide K (PSK) administration after curative surgical operation of colorectal cancer
10. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer
11. Randomized, controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer
12. Effects of the protein-bound polysacharide preparation, PSK on spontaneous breast cancer in mice
13. The effect of a protein-bound polysaccharide preparation, PS-K, on carcinogenesis in the glandular stomach of rats induced by N-methyl-N'-nitro- N-nitrosoguanidine
14. Effects of a protein-bound polysaccharide from a basidiomycetes against hepatocarcinogenesis induced by ′3-methyl-4-dimethylaminoazobenzene in rats
15. Towards the primary prevention of cancer
16. Can we prevent breast cancer?
17. Evolution of tumors and the impact of molecular oncology
18. Oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis
19. The multistep nature of cancer
20. Suppression of carcinogenesis: a role for TGF-β and related molecules in prevention of cancer
21. Spontaneous and induced preleukemia cells in C57BL/6 mice
22. Induction of leukemia in mice by irradiation and radiation leukemia virus variants
23. Leukemogenic, immunogenic and genetic properties of a thymotropic radiation leukemia virus
24. Clonal analysis of radiation leukemia virus (RadLV) induced leukemic and preleukemic cells
25. Quantitation, in vitro propagation and characterization of preleukemic cells induced by radiation leukemia virus
26. Induction of IL-4 secretion by the radiation leukemia virus (RadLV): role in autocrine growth stimulation of RadLV infected pre-leukemic cells
27. Treatment of premalignancy: prevention of lymphoma in radiation leukemia virus inoculated mice by cyclosporin A and immunotoxin
28. Continuous production of radiation leukemia virus in C57BL thymona tissue culture lines: purification of the leukemogenic virus
29. Immunologic characteristics in relation to high and low leukemogenic activity of radiation leukemia virus variants
30. In vitro generation of cytotoxic lymphocytes against radiation and radiation leukemia virus (RadLV) induced tumors: III. Suppression of anti-tumor immunity in vitro by lymphocytes of mice undergoing RadLV induced leukemogenesis
31. In vitro therapy of the BCL1 tumor: Effect of immunotoxin valency and deglycosylation of the ricin A chain
32. The T cell repertoire is heavily influenced by tolerance to polymorphic self antigens
33. Correlation between the Vβ4+CD8+ T cell population and the H-2d haplotype
34. T-cell receptor Vβ use predicts reactivity and tolerance to Mlsa-encoded antigens
35. Characterization of a murine monoclonal antibody specific for an allotypic determinant on T cell antigen receptor
36. The antigen specific, major histocompatibility complex-restricted receptor on T cells. VI. An antibody to a receptor allotype
37. Self-tolerance eliminates T cells specific for M1s-modified products of the major histocompatibility complex
38. T cell receptor specific monoclonal antibodies against a Vβ11 positive mouse T cell clones
39. A T cell receptor Vβ segment that imparts reactivity to a class II major histocompatibility complex product
40. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation
41. Superantigens
42. Potentiation of T cell immunity against radiation-leukemia-virus-induced lymphoma by polysaccharide K
43. Adoptive immunotherapy of human cancer: the cytokine cascade and monocyte activation following high-dose Interleukin 2 Bolus treatment
44. Patterns of cytokines released by peripheral blood leukocytes of normal donors and cancer patients during interleukin-2 activation in vitro
45. Production of tumor necrosis factor α and interferon γ in interleukin-2-treated melanoma patients: correlation with clinical toxicity
46. Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids
47. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines
48. Phase I trial of continuous infusion recombinant interleukin-2 and intermittent recombinant interferon-α2a: Clinical effects